763 Phase 1/2 dose escalation and dose expansion study of transCon TLR7/8 agonist alone or in combination with pembrolizumab in patients with locally advanced or metastatic solid tumor malignancies: initial results from dose escalation
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.